Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 12/20 | 0.61 |
| ▸ | EDNRB | P24530 | 8/20 | 0.61 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.61 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.61 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | TCF4 | P15884 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.61 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12351990 | 0.89 | EDNRA (0.63) | EDNRAEDNRBCYP2C9CYP2C19NPSR1 | |
| SCHEMBL2239616 | 0.81 | ALDH1A1 (0.65) | PSMB1PSMB5PSMB2CYP2C9CYP2C19 | |
| SCHEMBL2241087 | 0.79 | MAPT (0.76) | PSMB1PSMB5PSMB2CYP2C9CYP2C19 | |
| SCHEMBL2241314 | 0.77 | KMT2A (0.71) | PSMB1PSMB5PSMB2CYP2C9CYP2C19 | |
| SCHEMBL7857530 | 0.77 | EDNRA (1.00) | EDNRAEDNRBCYP2C9CYP2C19MEN1 | |
| SCHEMBL2242640 | 0.77 | ALDH1A1 (0.62) | PSMB1PSMB5PSMB2CYP2C9CYP2C19 | |
| SCHEMBL7716850 | 0.77 | EDNRA (1.00) | EDNRAEDNRBCYP2C9CYP2C19MEN1 | |
| SCHEMBL2243299 | 0.76 | ALDH1A1 (0.61) | PSMB1PSMB5PSMB2CYP2C9CYP2C19 | |
| SCHEMBL29392404 | 0.76 | ALDH1A1 (1.00) | PSMB1PSMB5PSMB2CYP2C9CYP2C19 | |
| SCHEMBL2243581 | 0.76 | ALDH1A1 (1.00) | PSMB1PSMB5PSMB2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673910-B2 | Proteasome inhibitors for selectively inducing apoptosis in cancer cells | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673910-B2 | Proteasome inhibitors for selectively inducing apoptosis in cancer cells | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673910-B2 | Proteasome inhibitors for selectively inducing apoptosis in cancer cells | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2014-03-18 | — | — | US | disclosed |
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2011-08-18 | — | — | US | disclosed |
| WO-2010005534-A2 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010005534-A2 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | PSMB7, PSMD7, PSMB6 | EDNRA 1443/4885EDNRB 1645/4885PSMB1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.